Surmodics will be acquired by GTCR for $43.00 per share, totaling $627 million. This 41.1% premium reflects Surmodics' advancements in surface modification for medical devices and IVD technologies.

Related Keywords

Gary Maharaj , Sean Cunningham , Surmodics Inc , Nasdaq Stock Exchange , Nasdaq Stock ,